Anish Thomas
YOU?
Author Swipe
View article: Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Berzosertib pharmacodynamic assessment
View article: Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Pharmacokinetic assessment
View article: Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Whole exome sequencing results
View article: Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Trial protocol dose limiting toxicity criteria
View article: Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
View article: Supplementary Figure S3 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S3 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
PK results vs toxicity
View article: Low-grade non–muscle-invasive urothelial carcinoma of the bladder in a 16-year-old boy with UGT1A1 polymorphism and Gilbert's syndrome: A case report
Low-grade non–muscle-invasive urothelial carcinoma of the bladder in a 16-year-old boy with UGT1A1 polymorphism and Gilbert's syndrome: A case report Open
Bladder cancer in the pediatric and adolescent population is exceedingly rare.Genetic susceptibility factors, including polymorphisms in phase II detoxifying enzymes, may play a role in early tumorigenesis. We report the case of a 16-year-…
View article: Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling Open
Despite mechanistic rationale for combining PARP inhibitors with topoisomerase I inhibitors, clinical use has been hindered by dose-limiting toxicities. We hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery wit…
View article: Foreign Direct Investment, Economic Growth, and Governance in China: An Empirical Study
Foreign Direct Investment, Economic Growth, and Governance in China: An Empirical Study Open
In this study, the direct and indirect effect of FDI on governance was analyzed using the ARDL model with data spanning from 1990 to 2023. The analysis looked at FDI interaction with economic growth and financial openness. An analytical fr…
View article: Automated detection and characterization of small cell lung cancer liver metastasis on computed tomography
Automated detection and characterization of small cell lung cancer liver metastasis on computed tomography Open
Targeted therapy requires accurate molecular characterization of disease, which imaging and AI may aid in determining.
View article: Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer Open
View article: Circulating Tumor Cells Are Detectable and Independent of PSA and PSMA-PET Metrics in Localized High-Risk and Biochemically Recurrent Prostate Cancer
Circulating Tumor Cells Are Detectable and Independent of PSA and PSMA-PET Metrics in Localized High-Risk and Biochemically Recurrent Prostate Cancer Open
Purpose This study evaluated the feasibility of detecting circulating tumor cells (CTCs) in localized high risk (HR) and biochemically recurrent (BCR) prostate cancer (PCa) patients and examined the correlation between CTCs, serum prostate…
View article: SCLC-TumorMiner: A Directly Accessible Genomics Resource for Precision Oncology – Big Data for Small Cells
SCLC-TumorMiner: A Directly Accessible Genomics Resource for Precision Oncology – Big Data for Small Cells Open
SUMMARY RNAseq and DNAseq are fast, cost-effective and quantitative methods to dissect cancer cells. However, for each sample, they generate thousands of data points, and comparing patient samples multiplies the complexity. To handle these…
View article: Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management Open
Small cell carcinoma of the bladder (SCCB) is a rare, aggressive malignancy that accounts for less than 1% of all bladder cancers. In this report, we highlight the clinical manifestations of SCCB (including epidemiology, cystoscopic and im…
View article: SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancer
SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancer Open
SMARCA4 and other components of the SWI/SNF chromatin remodeling complex have been implicated in various cancers. Yet, its role in small cell lung cancer (SCLC) tumorigenesis remains poorly understood. Genetically engineered mouse models (…
View article: Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation
Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation Open
Lamin A/C ( LMNA ), a key component of the nuclear envelope, is essential for maintaining nuclear integrity and genome organization [1]. While LMNA dysregulation has been implicated in genomic instability across cancer and aging, the under…
View article: 84P Targeting small cell lung cancer neuroendocrine heterogeneity via FGFR inhibition
84P Targeting small cell lung cancer neuroendocrine heterogeneity via FGFR inhibition Open
View article: Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor
Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor Open
Background Profiling circulating cell-free DNA (cfDNA) has become a fundamental practice in cancer medicine, but the effectiveness of cfDNA at elucidating tumor-derived molecular features has not been systematically compared to standard si…
View article: SurvSig: Harnessing gene expression signatures to uncover heterogeneity in lung neuroendocrine neoplasms
SurvSig: Harnessing gene expression signatures to uncover heterogeneity in lung neuroendocrine neoplasms Open
View article: Cardiovascular causes of pediatric chest pain: Case-based review
Cardiovascular causes of pediatric chest pain: Case-based review Open
View article: Metastatic organotropism in small cell lung cancer
Metastatic organotropism in small cell lung cancer Open
Metastasis is the leading cause of cancer-related deaths, yet its regulatory mechanisms are not fully understood. Small-cell lung cancer (SCLC) is the most metastatic form of lung cancer, with most patients presenting with widespread disea…
View article: ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer Open
Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB) and chemotherapy. Here, we show that inhibition of ataxia telangiectasia and ra…
View article: Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of…
View article: Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Pharmacokinetic assessment
View article: Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Berzosertib pharmacodynamic assessment
View article: Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Study Representativeness
View article: Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
View article: Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Comparison of treatment-related adverse events with the combination of berzosertib and topotecan
View article: Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Study Representativeness
View article: Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial Open
Whole exome sequencing results